Vita Genomics Overview
- Year Founded
-
2001
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$75M
- Investors
-
5
Vita Genomics General Information
Description
Developer of Genomics Biotechnology intended to provide leading genomics test service. The company focuses on the human genome and is committed to disease and single nucleotide Polymorphism (Single Nucleotide Polymorphism, SNP) association research, and engaged in pharmacogenomics (Pharmacogenomics) research and clinical application development, thereby identifying genes related to diseases common in Asia, such as liver and nasal cancer.
Contact Information
Website
www.vitagenomics.comCorporate Office
- 7th Floor, Number 6, Section 1
- Zhongxing Road, Wugu District
- New Taipei City, 248-72
- Taiwan
Corporate Office
- 7th Floor, Number 6, Section 1
- Zhongxing Road, Wugu District
- New Taipei City, 248-72
- Taiwan
Vita Genomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 01-Mar-2021 | $75M | Completed | Startup |
Vita Genomics Patents
Vita Genomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100028868-A1 | Responsiveness to therapy for liver disorders | Inactive | 29-Jul-2008 | ||
| US-20080161203-A1 | Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof | Inactive | 27-Dec-2006 | ||
| US-20070161006-A1 | Using variation in protein-tyrosine phosphatase receptor-type delta (ptprd) gene to characterize allelic forms associated with respiratory system disorders | Inactive | 10-Jan-2006 | ||
| US-20080187932-A1 | Using variation in protein-tyrosine phosphatase receptor-type delta (ptprd) gene to characterize allelic forms associated with respiratory system disorders | Active | 10-Jan-2006 | ||
| US-7604945-B2 | Using variation in protein-tyrosine phosphatase receptor-type delta (ptprd) gene to characterize allelic forms associated with respiratory system disorders | Inactive | 10-Jan-2006 | C12Q1/6883 |
Vita Genomics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cathay Life Insurance | Corporation | Minority | ||
| CDIB Capital Group | Asset Manager | Minority | ||
| Diamond Biofund | Venture Capital | Minority | ||
| Ho Tung Chemical | Corporation | Minority | ||
| National Development Fund of Taiwan | Sovereign Wealth Fund | Minority |
Vita Genomics FAQs
-
When was Vita Genomics founded?
Vita Genomics was founded in 2001.
-
Where is Vita Genomics headquartered?
Vita Genomics is headquartered in New Taipei City, Taiwan.
-
What industry is Vita Genomics in?
Vita Genomics’s primary industry is Drug Discovery.
-
Is Vita Genomics a private or public company?
Vita Genomics is a Private company.
-
What is Vita Genomics’s current revenue?
The current revenue for Vita Genomics is .
-
How much funding has Vita Genomics raised over time?
Vita Genomics has raised $75M.
-
Who are Vita Genomics’s investors?
Cathay Life Insurance, CDIB Capital Group, Diamond Biofund, Ho Tung Chemical, and National Development Fund of Taiwan have invested in Vita Genomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process